^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...Options for treatment of unresectable local, satellite, or in-transit recurrences include intralesional injection with T-VEC, ILP or ILIwith melphalan
Secondary therapy:
melphalan
